Travis Steed
Stock Analyst at Barclays
(2.91)
# 1,703
Out of 4,761 analysts
81
Total ratings
47.69%
Success rate
8.54%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $278 → $279 | $227.43 | +22.68% | 7 | Feb 14, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $73.30 | +22.78% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $24.69 | +29.61% | 1 | Nov 5, 2024 | |
| SOLV Solventum | Maintains: Neutral | $70 → $60 | $73.02 | -17.83% | 2 | Jun 25, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $33.82 | +33.06% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $32 → $3 | $0.88 | +242.70% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $382.78 | -17.71% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $282.80 | +4.31% | 3 | Aug 24, 2023 | |
| AXGN Axogen | Reiterates: Overweight | $16 | $18.00 | -11.11% | 5 | Aug 22, 2023 | |
| TNDM Tandem Diabetes Care | Downgrades: Underperform | $45 → $33 | $31.00 | +6.45% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $104.83 | +52.63% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $591.79 | -46.77% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $8.96 | -10.71% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $14.10 | +77.30% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 | $134.92 | +3.77% | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $18.90 | +349.74% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $88.78 | +40.80% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $89.94 | +61.22% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $104.49 | -51.19% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $61.13 | +186.28% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $21.13 | +155.56% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $78.23 | -71.88% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Feb 14, 2025
Maintains: Overweight
Price Target: $278 → $279
Current: $227.43
Upside: +22.68%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $73.30
Upside: +22.78%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $24.69
Upside: +29.61%
Solventum
Jun 25, 2024
Maintains: Neutral
Price Target: $70 → $60
Current: $73.02
Upside: -17.83%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $33.82
Upside: +33.06%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $32 → $3
Current: $0.88
Upside: +242.70%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $382.78
Upside: -17.71%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $282.80
Upside: +4.31%
Axogen
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $18.00
Upside: -11.11%
Tandem Diabetes Care
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $31.00
Upside: +6.45%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $104.83
Upside: +52.63%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $591.79
Upside: -46.77%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $8.96
Upside: -10.71%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $14.10
Upside: +77.30%
May 31, 2022
Maintains: Buy
Price Target: $140
Current: $134.92
Upside: +3.77%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $18.90
Upside: +349.74%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $88.78
Upside: +40.80%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $89.94
Upside: +61.22%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $104.49
Upside: -51.19%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $61.13
Upside: +186.28%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $21.13
Upside: +155.56%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $78.23
Upside: -71.88%